Oligodendrocyte Precursor Cells (OPC)

CLS-logo.png Understanding how to use Oligodendrocyte Precursor Cells (OPCs) to enhance remyelination in multiple sclerosis is key to bringing new treatments to the clinic.

We help you understand the role of your drug candidate on oligodendrocyte behavior and myelination.

OPC Assays

We offer screening using Oligodendrocyte Precursor Cells (OPCs). By assessing the effect of your drug candidate on OPC proliferation, differentiation and apoptosis, we can help you identify compounds with the potential to enhance myelination, bringing you on the best route to the clinic.

We are also developing a high-throughput 3D OPC culture assay and hope to offer human OPC assays in the near future.

We offer screening of primary oligodendrocyte progenitor (NG2+) cells. A promising therapeutic strategy for Multiple Sclerosis is to promote Oligodendrocyte Precursor Cells (OPC) differentiation and maturation into oligodendrocytes (MBP+ cells), repairing myelin degeneration. Understanding the effect of your drug candidate on OPCs to enhance remyelination early in discovery is key to bringing new treatments to clinic.

Understanding the remyelination efficiency of your drug candidate in three dimensions offers a translational link between in vitro cell culture and in vivo investigations, a step up in complexity from our screening assay, and your best route to clinic.

Using our organotypic brain slice assays, we can help you understand the functional effects of your compounds. We can determine the degree of axon (re)myelination by oligodendrocytes, during development or following demyelination, mimicking an MS lesion. We can tailor the assay readouts to your requirements e.g. fluorescent imaging and gene expression analysis by qPCR. To find out more click here.

How our OPC assay works

  • Mixed glial cultures are prepared and incubated according to protocol
  • OPCs are isolated and cultured with test compounds
  • Proliferation and apoptosis/toxicity readouts are assessed after 24 hours and differentiation after 7 days of treatment
  • High-resolution immunohistochemistry, combined with semi-automated image analysis techniques, allows accurate quantification of compound effects on OPCs